Company Encyclopedia
View More
name
Cerus
CERS.US
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced.
330.79 B
CERS.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
Health Care SuppliesIndustry
Industry Ranking22/42
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-27.78%E
    • Profit Margin-8.01%D
    • Gross Margin53.40%B
  • Growth ScoreB
    • Revenue YoY13.03%B
    • Net Profit YoY19.07%B
    • Total Assets YoY13.53%B
    • Net Assets YoY14.60%A
  • Cash ScoreC
    • Cash Flow Margin-1247.75%E
    • OCF YoY13.03%B
  • Operating ScoreA
    • Turnover0.98A
  • Debt ScoreD
    • Gearing Ratio71.09%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Cerus Chief Legal Officer Chrystal Jensen Reports Sale of Common Shares

    Chrystal Jensen, Chief Legal Officer of Cerus Corporation, reported the sale of common shares of the company. This information was published via EDGAR by Cerus Corporation on November 26, 2025. The news is generated by Public Technologies using AI and is not financial advice.

    Reuters·
    US
    CERS
    +5.53%
    Reuters·
    US
    CERS
    +5.53%

    Cerus Corporation: Strong Q3 Growth Overshadowed by Regulatory Delays and Uncertainty

    BTIG analyst Mark Massaro reiterated a Hold rating on Cerus Corporation (CERS) stock due to mixed factors. Despite strong Q3 growth driven by INTERCEPT products, regulatory delays in Europe and the U.S. create uncertainty. The CE marking for INTERCEPT Red Blood Cells is delayed by six months, with potential further delays to 2027 in Europe and 2028 in the U.S. Massaro maintains a Neutral stance, acknowledging growth potential and challenges. Another report also reiterated a Hold rating with a $1.50 price target.

    Tip Ranks·
    US
    CERS
    +5.53%
    Tip Ranks·
    US
    CERS
    +5.53%

    Cerus Corporation’s Q3 2025 Earnings: Growth Amid Challenges

    Cerus Corporation reported strong Q3 2025 earnings, achieving record product revenue of $52.7 million, a 15% increase year-over-year. The company raised its full-year revenue guidance to $202-$204 million, driven by demand for INTERCEPT products, particularly the INTERCEPT Fibrinogen Complex, which saw a 70% revenue increase. Despite facing gross margin pressures and regulatory delays in Europe, Cerus remains optimistic about future growth and operational execution, with positive adjusted EBITDA of $5 million for the quarter.

    Tip Ranks·
    US
    CERS
    +5.53%
    Tip Ranks·
    US
    CERS
    +5.53%

    Cantor Fitzgerald Keeps Their Buy Rating on Cerus (CERS)

    Cantor Fitzgerald analyst Ross Osborn maintained a Buy rating on Cerus (CERS) with a price target of $4.00. Osborn, who focuses on the Healthcare sector, has an average return of -6.5% and a 28.81% success rate on his stock recommendations. Cerus also received a Buy rating from Craig-Hallum’s William Bonello recently, while TR | OpenAI reiterated a Hold rating on the stock on October 30.

    Tip Ranks·
    US
    CERS
    +5.53%
    Tip Ranks·
    US
    CERS
    +5.53%

    Cerus | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 60.24 M

    LB filings·
    US
    CERS
    +5.53%
    LB filings·
    US
    CERS
    +5.53%
    © 2025 Longbridge｜Disclaimer